FDA Determines Regulatory Review Period for NOURIANZ Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for NOURIANZ, a pharmaceutical company, in relation to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).